For instance, a study by Ming et al. involving RNA sequencing of PBMCs from 33 treatment-naïve BC patients (16 luminal A, 6 luminal B, 3 HER2-positive, and 8 TNBC) revealed that the established BC subtypes based on ER, PR, and HER2 were not associated with transcriptome-wide PBMC gene expression profiles [97]. The gene discussed is ERBB2; the disease is breast cancer.